PTV Sciences - Media Center

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test CE Mark for VerifyNow II System Caps a Strong 2012 for Accumetrics 8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012 Accumetrics Aligned with Medicare’s Hospital Readmissions Reduction Program Accumetrics’ VerifyNow System Receives Health Canada License for Clinical Use New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test Accumetrics Signs National Distribution Agreement with Cardinal Health 2011 ACCF/AHA Guidelines Incorporate New Recommendations for Platelet Reactivity Testing back to top


Alereon Introduces New Wireless HDMI Video Solutions Ultrawideband: Down, But Far From Out WiMedia and UWB: where to from here? Alereon Receives FCC Modular Certification for Worldwide Wireless USB Half-MiniCard back to top

Apollo Endosurgery’s OverStitch™ Endoscopic Suturing Platform Launches in Europe Apollo Endosurgery Named to FierceMedicalDevices “FIERCE 15” List of Top Private Medical Device Companies of 2012 Apollo Names Former Covidien Chairman and CEO Richard Meelia to Board FDA Clears Apollo Endosurgery’s SuMO™ Endoscopic Tissue Access and Resection System Apollo Endosurgery Announces First Incisionless Full-thickness Resection of a Colonic Polyp Apollo Endosurgery Taps Michael Doty for CFO New Class of Instruments for Flexible Surgery from Apollo Endosurgery Used in Cancer Therapy Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ back to top

Asuragen launches SuraSeq™ Next Generation Sequencing Services Rolland Carlson, Ph.D. named CEO of Asuragen Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine Asuragen Grants Armored RNA® Technology License to BD Asuragen awarded $6.8 million commercialization award from CPRIT Asuragen announces launch of Inform^TM Thyroid Panel Asuragen Reports Results from a Multi-Center Study on Fragile X Gene Asuragen Announces New Notices of Allowance from USPTO Related to the Diagnostic Applications of Cancer-Related miRNAs back to top

(NASDAQ: BFRM) - Acquired by: Merz Merz to Acquire BioForm Medical back to top

(NASDAQ: BMTI) BioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical Trial Wright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter Into Agreement to Combine Businesses BioMimetic Therapeutics' Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Committee BioMimetic Therapeutics, Inc. to Highlight Commercial and Product Development Activities during AAOS BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment(TM) Bone Graft BioMimetic Therapeutics PMA Remains on Track BioMimetic nears European patent on tissue healing products Dr. Samuel E. Lynch Presides Over NASDAQ Closing Bell to Celebrate Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI] back to top

Brookhaven Lab and BioSET, Inc., Patent a Synthetic Peptide That Enhances Bone Growth BioSET Announces Initiation Of Clinical Trials For AMPLEX Osteo-Promotive Bone Graft System For Spine Fusion Tornier and Bioset Enter Synthetic Growth Factor Pact back to top

Boston Scientific Wins FDA Approval for Under-Skin Defibrillator Cameron Health's S-ICD System Meets Primary Safety and Efficacy Endpoints in IDE Clinical Study "A Life Saver" - Patient Article in the UK Cameron Health's S-ICD System Scheduled for FDA Panel Review on April 26, 2012 Boston Scientific to Acquire Cameron Health, Inc. Cameron Health Patient in the News - NCAA.com Aritcle back to top

Cardiva Medical, Inc. Announces U.S. FDA Approval for VASCADE™ Vascular Closure System Cardiva Medical, Inc. announces that it has obtained approval to apply the European CE Mark to its VASCADE™ Closure System Cardiva Medical, Inc. submits final PMA module to FDA for VASCADE™ Vascular Closure Cardiva Medical, Inc. Announces Completion of Enrollment in the RESPECT Clinical Trial Cardiva Medical, Inc. Announces U.S. Distribution for Hemostasis Products Cardiva Medical, Inc. Announces Appointment of Charles Maroney, President and Chief Executive Officer Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst III System back to top

Glycomimetics Completes Enrollment in Phase 2 Sickle Cell Disease Study with Lead Drug Candidate GMI-1070 GlycoMimetics Presented Progress from its Novel Compounds at 2012 American Society of Hematology Annual Meeting GlycoMimetics Announces Two Key Leadership Promotions GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patients GlycoMimetics, Inc. Awarded NIH Grant to Study Drug Candidate in Diabetes back to top

Twelve-Month Outcomes of Popliteal Artery Treatment with Supera® System Published in JACC Cardiovascular Interventions Results from RESTORE Study Demonstrate Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions Clinical Results for the Supera® Peripheral Stent System Highlighted At Leading Global Peripheral Intervention Course New Tactics To Treat Artery Disease That Harms Legs IDEV Announces Positive Two-Year Clinical Outcomes from Long Term Registry of the SUPERA® Stent IDEV's Pivotal SUPERB Trial Demonstrates SUPERA® Stent Significantly Exceeds VIVA Criteria for One-Year Patency IDEV seeks to secure PMA for Supera stent IDEV Technologies Introduces SUREPATH™ Guidewires IDEV Technologies Strengthens Commercial Leadership back to top

(INSV.OB) InSite Vision Initiates Confirmatory Phase 3 Study of BromSite™ for Reduction of Inflammation and Pain after Cataract Surgery InSite Vision Completes Phase 3 Clinical Study of BromSite for the Reduction of Pain and Inflammation After Cataract Surgery InSite Vision Fully Enrolls Phase 3 Clinical Study of BromSite™ for the Reduction of Pain and Inflammation after Cataract Surgery InSite Vision Introduces DuraSite 2® Ophthalmic Drug Delivery System InSite Vision Initiates First Phase 3 Clinical Study of BromSite™ for the Reduction of Pain and Inflammation after Cataract Surgery InSite Vision Receives Broad Patent Approval in Japan InSite Vision Receives Special Protocol Assessment from FDA for DOUBle Phase 3 Clinical Trial of AzaSite Plus & DexaSite back to top

Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business” Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters” Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant PROPEL Wins Internationally-Renowned Edison Award Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif. Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant Intersect ENT Announces U.S. FDA Approval for First Drug Releasing Implant for Chronic Sinusitis Patients back to top

LDR Receives Approvable Letter from U.S. Food and Drug Administration for Two-Level Mobi-C® Cervical Disc LDR Announces FDA Clearance of the Avenue® L Lateral Lumbar Cage System LDR Announces FDA Clearance and Launch of the ROI-C® Lordotic Cervical Cage LDR Holding Appoints Robert E. McNamara Chief Financial Officer LDR Opens New and Expanded Global Headquarters in Austin, Texas LDR receives approval to market two new stand-alone spine products in China LDR Founder, President and CEO Named a 2011 Ernst & Young Entrepreneur Of The Year^® for the Central Texas Region back to top

Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors Mirna Therapeutics Publishes Preclinical Data Demonstrating Therapeutic Effects of microRNA in Hematological Cancer Marina Biotech and Mirna Therapeutics Announce License Mirna Therapeutics to Moderate Session on Promise of miRNAs in Cancer at BIO International Convention Mirna Therapeutics and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells Mirna Therapeutics reports notice of allowance from USPTO related to clinical application of an important cancer-related miRNA back to top

Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups for On-X Prosthetic Heart Valve Anticoagulation Clinical Study AATS Report: Prospective Randomized On-X Heart Valve Clinical Trial (PROACT) Provides Evidence of Reduced Complications Predicting Long-Term Costs of Heart Valve Replacement Study to be Presented at American College of Cardiology Meeting On-X LTI Receives FDA Approval for On-X Heart Valve with Anatomic Shaped Sewing Ring On-X LTI Launches CHORD-X™ ePTFE Suture for Mitral Valve Repair and Replacement at STS 2013 On-X Life Technologies Submits for FDA/CE Approval of Reduced Anticoagulation Indication for On-X Aortic Heart Valve On-X LTI Launches Innovative Heart Valve Products at European Meeting in Barcelona The On-X® Heart Valve Compares Favorably to Tissue Valves Austin Company Keeps GI's Heart Beating back to top

KineGraph Study: Finding the Right Patient Gov. Perry: We Must Invest Wisely to Help Texans and Strengthen Our Economy back to top

Smith & Nephew Acquires OBI, Inc. back to top

Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT Stent Tryton Medical Announces Events at EuroPCR 2013 in Paris Tryton Medical Announces Completion of Patient Enrollment in Landmark Pivotal Study Tryton Announces Postive Clinical Data from More Than 900 Patients 4000th Patient Treated With Innovative Tryton Side Branch Stent Tryton Announces Positive Data from Three European Registries Shawn P. McCarthy Appointed President and CEO of Tryton Medical Tryton Announces Enrollment of First U.S. Patient in Pivotal Study of Side Branch Stent Tryton Announces Investigational Device Exemption Conditional Approval from FDA TRYTON Announces Registry Evaluating Tryton Stent System for Left Main Disease and Celebrates 500th Implant back to top

(NASDAQ: ZIOP) ZIOPHARM Reports Positive Preliminary Palifosfamide Overall Survival Data from Randomized Phase 2 Study ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of Palifosfamide in Small Cell Lung and Other Cancers ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium back to top